1 active not recruiting, 1 approved for marketing. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow CellTrans Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol Islets of Langerhans transplantation - Type 1 Diabetes Mellitus | Phase 3 | Active not recruiting | CellTrans Inc. | 21 | 2007-09-05 | 2026-04-06 |
| Islet Transplantation in Type I Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol Donislecel (allogeneic islets of Langerhans for transplant) - Type 1 Diabetes Mellitus | Approved for marketing | CellTrans Inc. | 2024-10-22 |
Basiliximab (1) · Etanercept (1) · Exenatide (1) · Islets of Langerhans Transplantation (1) · Sirolimus (1) · Tacrolimus (1) · Transplantation (1)
United States (2)